Why don’t patients know how to access the breakthrough advances being made by genomic medicine?
Why can’t we use technology to transform how people access the service that matters most — cancer treatment?
These are the questions that kept us up at night.
Cure Forward is the vision of a small team in Boston, MA. We want to create a platform to connect patients with clinical trials, bringing the possibilities of precision medicine directly in reach. A way to use the best of technology to help people diagnosed with life-altering disease discover all their options. We want to make it easy for patients to understand the root cause of their conditions and put the knowledge to work.
We felt making this happen was worth staying up all night.
HOW IT WORKS
We teach patients about molecular diagnostic testing, precision medicine and clinical trials. This is the first step for helping them understand what is happening in their bodies and potential treatment options.
We connect patients with others just like them – down to the molecular level. Patients ask questions and get knowledge from survivors, patients and caregivers who share the same mutation behind their cancer.
Clinical trials may be an important option in patient’s treatment plans but they are often hard to find. We reverse the search process and allow patients the opportunity to be seen by recruiters across the country. If there is a potential match recruiters reach out to the patients – it is the end of scouring the internet.
Chief Executive Officer Frank Ingari has served the consumer, healthcare and information technology industries for the past 35 years. He previously held CEO appointments at NaviNet, 5-Star Medicare Advantage plan Essence Healthcare, and Best-in-KLAS Value-Based Care Service Provider Lumeris, which Ingari co-founded. His leadership capabilities have resulted in notable successes across numerous high-growth companies. As CEO of Navinet, Ingari was instrumental in driving strategic growth for the nation’s leading healthcare technology supplier of payer-provider collaboration solutions, culminating in a sale to NantHealth in January 2016.
Founder & Chief Strategy Officer
Martin has been pushing boundaries his entire career. He established some of the first tests to read a tumor’s DNA profile using next-generation sequencing over a fifteen-year career at Life Technologies. But frustrated by how hard it was to understand and access the amazing benefits of genomic medicine, he founded Cure Forward. Here, he is fundamentally changing the way people approach their disease by making genomics understandable and within reach. In his scant spare time, you’ll find Martin on one of his bicycles, skiing, stand-up paddle surfing or spending time with his wife and two young children.
Chief Financial Officer
Sean Bridgeo is the Chief Financial Officer at Cure Forward overseeing accounting, finance, tax, procurement, legal affairs, human resources and compliance. Sean believes financial leadership is most effective as a collaborative partner to business teams in strategic and operational decision making.Most recently Sean was a member of the executive team at Navinet, a leading Healthcare information technology company specializing in data connectivity and exchange between payers and providers. As CFO he played a key role in executing a successful sale of the company to Nant Health.
Sean lives in Lexington, MA with his wife and 2 children and enjoys spending his free time exploring the outdoors and playing the occasional round of golf.
Chief Marketing Officer
Stacey has built her career telling stories that beg to be shared. A digital marketing executive for start-ups and established global brands, Stacey is the driver of insight and data driven marketing programs that meet the consumer online and offline, break through the clutter and create virality. After honing her voice and craft as a member of the founding team of Ruelala.com and with leading brands including Reebok, she is now focused on telling the story of precision medicine. At Cure Forward, Stacey is opening up new conversations between patients, caregivers and healthcare providers. As a mother of three, she also enjoys all activities involving her husband and active kids.
Chief Medical Advisor
Professor Andrew Biankin is the Regius Chair of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist and Wellcome Trust Senior Investigator. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision medicine. He has authored over 100 articles in major journals including seminal works on cancer, genomics and precision medicine. He sits on several international expert panels and is an international leader and expert in precision oncology. Originally from Australia, Andrew finds Scotland also very much to his liking.
Chief Technology Officer
Doug is passionate and naturally curious, deep technology leader, with a track record of architecting and delivering world class innovative software platforms and exemplary technology teams. Doug most recently led the major technology and team transformation for ikaSystems, a leader in health plan back office operations. Prior to ikaSystems, Doug led the definition and build out of Pneuron’s award winning big data and distributed systems software platform. Before Pneuron, Doug led the definition and delivery of an advanced healthcare platform-as-a-service platform with rich medication and disease protocol engagement and intervention for patients. Doug has tremendous passion and interest in big data, predictive modeling, and distilling actionable intelligence from data and analytics.
VP Business Development
Melissa has spent her healthcare career in business development. In past years, she has promoted a leading prostate cancer drug, introduced minimally invasive surgical instruments to the US market and, after leaving the west coast, focused on promoting services for oncology trials including image analysis, patient recruitment and retention and CRO support. As head of business development, Melissa works with Clinical Trial Recruiters to improve their study enrollment timelines. When she isn’t helping our trial partners, Melissa could be found somewhere in Vermont on a golf course, ski hill or sports field with her very active family.